CompletedPhase 2ACTRN12614000873628

A pilot randomised controlled trial of omega-3 fatty acid supplements to prevent skin cancer in lung transplant recipients


Sponsor

QIMR Berghofer Medical Research Institute

Enrollment

100 participants

Start Date

Dec 15, 2014

Study Type

Interventional

Conditions

Summary

This study aims to evaluate the effectiveness of fish oil for the prevention of skin cancer in lung transplant recipients. Who is it for? You may be eligible to join the study if you are over 18 years of age, and are a lung transplant recipient for at least 1 year. Study details Participants in this study are randomly allocated (by chance) to one of two groups. Participants in one group will take 4 x 1000mg oral capsule of omega-3 fish oil supplement daily for 12 months. Participants in the other group will take 4 x 1000mg of placebo (olive oil) daily for 12 months. Participants will not know which treatment they are taking until the end of the study. All participants will be asked to complete questionnaires, blood tests and skin exams at baseline and at the end of the study at 12 months.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria4

  • Male and female lung transplant recipients Greater than or equal to 18 years of age.
  • Greater than or equal to 1 year post lung transplant.
  • Use of systemic retinoid therapy permitted if on stable dosing for previous 3 months.
  • Will be able to attend the clinic for at least Visit 1 and Visit 4 within the recruitment timeframe.

Exclusion Criteria9

  • Unable to give informed consent.
  • Have innately black or dark brown skin.
  • Have a fish allergy.
  • Have a soya allergy.
  • Unable to take gelatin.
  • Have a bleeding disorder or bleeding episode in last 3 months
  • Are receiving warfarin, heparin or low molecular weight heparin in therapeutic doses. (Patients receiving heparin or low molecular weight heparin in prophylactic doses will not be excluded)
  • Are already taking fish oil supplements and unwilling to discontinue for 2 months before randomisation and for trial period.
  • Pregnant

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

A pilot trial of a double-blind, placebo-controlled, randomized study with 2 arms. Arm1: Participants will receive 4 x 1000mg oral capsule of omega-3-acid ethyl esters 90, a fish oil supplement (A

A pilot trial of a double-blind, placebo-controlled, randomized study with 2 arms. Arm1: Participants will receive 4 x 1000mg oral capsule of omega-3-acid ethyl esters 90, a fish oil supplement (Active) taken daily for 12 month Arm 2: Participants will receive 4 x 1000mg capsules of olive oil (Placebo) taken daily for 12 months. Any unused capsules will be returned to study Doctors on follow up visits.


Locations(1)

The Prince Charles Hospital - Chermside

QLD, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12614000873628


Related Trials